Abstract 1110P
Background
Immune checkpoint inhibitors (ICIs) have limited efficacy in advanced melanoma in Asians, and chemotherapy is still an important option. Temozolomide (TMZ) has been recommended in guidelines for treatment of melanoma. SHR-1701 is a bifunctional fusion protein composed of a mAb against PD-L1 fused to the extracellular domain of TGF-β receptor II. Here, we report the safety and efficacy of SHR-1701 combined with TMZ in advanced melanoma.
Methods
In this single-center, phase II study, patients(pts) with advanced melanoma were eligible. Prior ICIs plus TMZ and progressed within 6 months was not permitted. Pts received SHR-1701(30 mg/kg IV Q3W) combined with TMZ (150 mg/m2 IV, Days 1-5 Q3W) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) per RECIST1.1. Secondary endpoints included progression free survival (PFS), disease control rate (DCR), overall survival (OS), and safety. A standard Simon two-stage design was used. If there were more than 5 responses in 21 pts in stage I, the study would continue to 31 pts in stage II.
Results
As of March 31, 2023, 21 pts were enrolled. Various histology subtypes were included (16 acral, 2 mucosal, 2 cutaneous, 1 unknown histology subtype). The median age was 54 years (range, 34-73), most patients were male (52.4%), 18 pts (85.7%) were ECOG PS 1, 15 pts (71.4%) were stage IV. Received previous 0/1/2 lines of systemic treatment were 14(66.7%)/4(19.0%)/3(14.3%) pts. The median follow-up was 4.4 months(range, 0.5 to 12.7 months). At the data cutoff, 12 pts remained on treatment. Of 16 evaluable pts, 7 pts had partial response, and 6 pts had stable disease. The unconfirmed ORR and DCR were 43.8% and 81.3%, respectively. After treatment, 3 pts with solitarily metastatic lesions received curative surgery. Of 21 pts, the incidence of treatment-related adverse events (TRAEs) was 47.6%, most commonly anemia, γ-glutamyltransferase increase and rash (14.3% each). The incidence of grade 3 TRAEs was 14.3%. No grade ≥ 4 TRAEs occurred.
Conclusions
SHR-1701 plus TMZ showed promising antitumor activity in advanced melanoma pts, and was generally well tolerated.
Clinical trial identification
NCT05106023; released in November 3, 2021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1171P - Evaluation of the transcriptomic presence of tumor associated antigens (TAAs) from antibody drug conjugates (ADCs) and PD-L1 in melanoma: Options for new clinical opportunities
Presenter: Jorge Bartolome
Session: Poster session 13
1172P - Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
Presenter: Marin Golcic
Session: Poster session 13
1173P - NRAS mutation as an independent prognostic factor for resectable Chinese acral melanoma
Presenter: Yu Xu
Session: Poster session 13
1174P - Sex differences in advanced melanoma in Spain: Results from the prospective real-world study GEM 1801
Presenter: Eva Muñoz Couselo
Session: Poster session 13
1175P - Return to work after neoadjuvant versus adjuvant immunotherapy in stage III melanoma patients
Presenter: Judith Lijnsvelt
Session: Poster session 13
1176P - Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
Presenter: Anna Czarnecka
Session: Poster session 13
1177P - Assessment of tumour burden reduction per photography vs magnetic resonance imaging in patients with locally advanced basal cell carcinoma receiving sonidegib 200 mg
Presenter: Ralf Gutzmer
Session: Poster session 13
1178P - Melanoma incidence rises for pediatrics: 15-year nationwide retrospective cohort study in Korea (2004-2019)
Presenter: Jisu Oh
Session: Poster session 13
1179P - The underestimated skin cancer risk after liver transplantation: A meta-analysis of 147154 patients
Presenter: Amr Ehab El-Qushayri
Session: Poster session 13